DNA-cytometric parameters in patients with ovarian cancer

Cover Page

Abstract


Aim. To study DNA flow cytometry parameters in patients with stage III-IV ovarian cancer receiving different treatments. Methods. Surgical material obtained from 93 female patients with verified stage III-IV ovarian cancer was studied. Patients were divided into 4 groups depending on the treatment variant: without neoadjuvant chemotherapy, with neoadjuvant chemotherapy, with neoadjuvant chemotherapy with different recombinant human interferon gamma (Ingaron) injections - intramuscular or intraperitoneal. Cell count was analyzed, and ploidy interpretation and cell cycle analysis were performed on fresh surgical material. Results. Differences in cell distribution depending on the treatment method were found. Increased proliferation rates, proliferation index, aneuploid tumors predominance in the group without drug exposure were demonstrated. Most of diploid tumours were registered in the group receiving neoadjuvant chemoimmunotherapy with intraperitoneal immunomodulator injections (83.4%) that indicates better disease prognosis. Under exposure to neoadjuvant polychemotherapy aneuploid cell number decreases to 38.4%, and chemoimmunotherapy with intramuscular and intraperitoneal recombinant human interferon gamma injections demonstrated even greater decrease - to 27.2 and 16.6%, respectively. Conclusion. Interferon gamma inclusion into the treatment contributes to a decreased number of aneuploid tumors, reduced proportion of aneuploid cells in tumors and reduced proliferation rates and proliferation index characterizing cancer aggressiveness.

G A Nerodo

Author for correspondence.
mordan-anna@yandex.ru
Rostov Scientific Research Institute of Oncology Rostov-on-Don, Russia

I A Novikova

mordan-anna@yandex.ru
Rostov Scientific Research Institute of Oncology Rostov-on-Don, Russia

A Yu Ardzha

mordan-anna@yandex.ru
Rostov Scientific Research Institute of Oncology Rostov-on-Don, Russia

V P Nikitina

mordan-anna@yandex.ru
Rostov Scientific Research Institute of Oncology Rostov-on-Don, Russia

I A Kosenko

mordan-anna@yandex.ru
N.N. Alexandrov National Cancer Center of Belarus Minsk, Republic of Belarus

O E Kravtsova

mordan-anna@yandex.ru
Rostov Scientific Research Institute of Oncology Rostov-on-Don, Russia

E S Bondarenko

mordan-anna@yandex.ru
Rostov Scientific Research Institute of Oncology Rostov-on-Don, Russia

  • Jemal A., Siegel R., Xu J. et al. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60: 277-300. doi: 10.3322/caac.20073.
  • Руководство по химиотерапии опухолевых заболеваний. Под ред. Н.И. Переводчиковой, В.А. Горбуновой. М.: Практическая медицина. 2015; 259-260.
  • Kaern J., Aqhmeshen M., Nesland J.M. et al. Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short-and long-term surviors? Int. J. Gynecol. Cancer. 2005; 15 (6): 1014-1022.
  • Войткова В.В. Изучение апоптоза методом проточной цитофлуориметрии (обзор литературы). Бюлл. ВСНЦ СО РАМН. 2010; (6-1): 220-225.
  • Неродо Г.А., Непомнящая Е.М., Новикова И.А. и др. ДНК-цитометрический анализ параметров клеточного цикла рака тела матки у молодых женщин. Мед. наука и образование Урала. 2011; 2: 89-91.
  • Неродо Г.А., Новикова И.А., Никитина В.П. и др. Клиническое значение ДНК проточной цитометрии при раке яичников. Соврем. пробл. науки и образования. 2016; 3. https://science-education.ru/ru/article/view?id=24485 (дата обращения: 13.03.2017).
  • Николаева Т.Г., Добрынин Я.В. Плоидность опухолевых клеток - важный прогностический фактор при некоторых злокачественных эпителиальных новообразованиях человека (собственные и литературные данные). Вестн. РОНЦ им. Н.Н. Блохина РАМН. 2006; 17 (1): 29-35.
  • Vielh P., Carton M., Padoy E. et al. S-phase fraction as an independent prognostic factor of long-term overall survival in patients with early-stage or locally advanced invasive breast carcinoma. Cancer. 2005; 105 (6): 476-482. doi: 10.1002/cncr.21348.
  • Danielsen H.E., Pradhan M., Novelli M. Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era. Nat. Rev. Clin. Oncol. 2016; 13 (5): 291-304. doi: 10.1038/nrclinonc.2015.208.
  • Novikova I., Nerodo G., Mordan A. Comparative anaiysis of DNA-cytometric indices of primary and relapsing ovarian cаncer. J. Clin. Oncol. 2013; 31 (suppl.): e16558.
  • Неродо Г.А., Новикова И.А., Мордань А.Ю. Способ прогнозирования рецидива рака яичников. Патент РФ №2530556. Бюлл. №28 от 10.10.2014.
  • Zargoun I.M., Bingle L., Speight P.M. DNA ploidy and cell cycle protein expression in oral squamous cell carcinomas with and without lymph node metastases. J. Oral. Pathol. Med. 2017 Jan. 30. http://eprints.whiterose.ac.uk/112241/ (access date: 02.03.2017). doi: 10.1111/jop.12554.

Views

Abstract - 119

PDF (Russian) - 67


© 2017 Nerodo G.A., Novikova I.A., Ardzha A.Y., Nikitina V.P., Kosenko I.A., Kravtsova O.E., Bondarenko E.S.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.